Pathological changes in the pancreas of fulminant type 1 diabetes and slowly progressive insulin-dependent diabetes mellitus (SPIDDM): Innate immunity in fulminant type 1 diabetes and SPIDDM

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 8, 2011, Pages 965-970

  Kobayashi, Tetsuro ^a   Nishida, Yoriko ^a   Tanaka, Shoichiro ^a   Aida, Kaoru ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

CXCL10; Diabetes; Fulminant type 1; Innate immunity; LGP2; MDA5; RIG I; Slowly progressive insulin dependent diabetes mellitus

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; INFLUENZA VIRUS A PROTEIN; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 PROTEIN; PROTEIN VP1; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BRAIN INFARCTION; CASE REPORT; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; ENTEROVIRUS; EPIGASTRIC PAIN; FEMALE; FEVER; FULMINANT INSULIN DEPENDENT DIABETES MELLITUS; GENETICS; HAPLOTYPE; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLUENZA VIRUS A; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; MALE; MONONUCLEAR CELL; NAUSEA; NAUSEA AND VOMITING; PANCREAS DISEASE; PANCREAS ISLET CELL; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SLOWLY PROGRESSIVE INSULIN DEPENDENT DIABETES MELLITUS;

ADOLESCENT; ADULT; DEAD-BOX RNA HELICASES; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; DISEASE PROGRESSION; ENTEROVIRUS INFECTIONS; HUMANS; IMMUNITY, INNATE; INTERFERON-ALPHA; INTERFERON-BETA; ISLETS OF LANGERHANS; MALE; PANCREAS; RNA HELICASES; TOLL-LIKE RECEPTORS; VIRAL STRUCTURAL PROTEINS;

EID: 80855124098     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1237     Document Type: Article

References (27)

1. Kobayashi T. Immunology and immunogenetics of type 1 diabetes in Japan. IDF Bulletin 1990; 35: 34-37.
2. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000; 342: 301-307.
3. Tanaka S, Kobayashi T, Momotsu T. A novel subtype of type 1 diabetes mellitus. N Engl J Med 2000; 342: 1835-1837.
4. Tanaka S, Nishida Y, Aida K, et al. Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes 2009; 58: 2285-2291.
5. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol 2008; 20: 17-22.
6. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 2008; 1143: 1-20.
7. von Herrath M. Diabetes: A virus-gene collaboration. Nature 2009; 459: 518-519.
8. Sano H, Terasaki J, Tsutsumi C, Imagawa A, Hanafusa T. A case of fulminant type 1 diabetes mellitus after influenza B infection. Diabetes Res Clin Pract 2008; 79: e8-e9.
9. Kobayashi T, Itoh T, Kosaka K, Sato K, Tsuji K. Time course of islet cell antibodies and beta-cell function in non-insulin-dependent stage of type I diabetes. Diabetes 1987; 36: 510-517.
10. Kobayashi T, Nakanishi K, Sugimoto T, et al. Maleness as risk factor for slowly progressive IDDM. Diabetes Care 1989; 12: 7-11.
11. Kobayashi T. Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: slowly progressive IDDM-the clinical characteristics and pathogenesis of the syndrome. Diabetes Res Clin Pract 1994; 24 (Suppl.): S95-S99.
12. Kobayashi T, Tamemoto K, Nakanishi K, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 1993; 16: 780-788.
13. Tanaka S, Kobayashi T, Nakanishi K, et al. Association of HLA-DQ genotype in autoantibody-negative and rapid-onset type 1 diabetes. Diabetes Care 2002; 25: 2302-2307.
14. Oberste MS, Maher K, Flemister MR, Marchetti G, Kilpatrick DR, Pallansch MA. Comparison of classic and molecular approaches for the identification of untypeable enteroviruses. J Clin Microbiol 2000; 38: 1170-1174.
15. Nix WA, Berger MM, Oberste MS, et al. Failure to detect enterovirus in the spinal cord of ALS patients using a sensitive RT-PCR method. Neurology 2004; 62: 1372-1377.
16. Nix WA, Oberste MS, Pallansch MA. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. J Clin Microbiol 2006; 44: 2698-2704.
17. Lönnrot M, Korpela K, Knip M, et al. Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention Study. Diabetes 2000; 49: 1314-1318.
18. Dierssen U, Rehren F, Henke-Gendo C, Harste G, Heim A. Rapid routine detection of enterovirus RNA in cerebrospinal fluid by a one-step real-time-PCR assay. J Clin Virol 2008; 42: 58-64.
19. Verstrepen WA, Kuhn S, Kockx MM, van de Vyvere ME, Mertens AH. Rapid detection of enterovirus RNA in cerebrospinal fluid specimens with a novel single-tube real-time reverse transcription-PCR assay. J Clin Microbiol 2001; 39: 4093-4096.
20. Aida K, Nishida Y, Tanaka S, et al. RIG-I- and MDA5-initiated innate immunity linked with adaptive immunity accelerates {beta}-cell death in fulminant type 1 diabetes. Diabetes 2011; 60: 884-889.
21. Satoh T, Kato H, Kumagai Y, et al. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc Natl Acad Sci U S A 2010; 107(26): 1512-1517.
22. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009; 324: 387-389.
23. Yoneyama M, Kikuchi M, Matsumoto K, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005; 175: 2851-2858.
24. Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW. MDA5 and MAVS mediate type I IFN responses to Coxsackie B virus. J Virol 2010; 84: 254-260.
25. Dogusan Z, García M, Flamez D, et al. Double-stranded RNA induces pancreatic beta-cell apoptosis by activation of the toll-like receptor 3 and interferon regulatory factor 3 pathways. Diabetes 2008; 57: 1236-1245.
26. Negishi H, Osawa T, Ogami K, et al. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci U S A 2008; 105: 20446-20451.
27. Tanaka S, Endo T, Aida K, Kobayashi T. Longitudinal changes in beta-cell function in the patients with slowly progressive insulin-dependent diabetes mellitus (SPIDDM). J Jap Diab Soc 2008; 51 (Suppl. 1): S-316 (Abstract).